Drugs / Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01454596 | May 2012 → Nov 2018 | gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01454596 ↗ |
| Action | Deplete | “Three of these anti-EGFRvIII CAR-engineered T cells produced the effector cytokine, interferon-γ, and lysed antigen-expressing target cells.” PMID 22780919 ↗ Sep 2012 |
| Modality | Cell therapy | “development of adoptive cell therapy for glioma.” PMID 22780919 ↗ Sep 2012 |
| Route | Intravenous | “Cells will be infused intravenously over 20-30 minutes.” NCT01454596 ↗ |